NCT00415714Unknown不适用
A Randomized Controlled Pilot Trial Testing the Safety and Efficacy of an Ambulatory Biofeedback Device for Primary Insomnia
Helicor2 个研究点 分布在 1 个国家目标入组 132 人开始时间: 2006年9月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 132
- 试验地点
- 2
- 主要终点
- Sleep latency at 4 week follow-up
研究概览
简要总结
The objective of this study is to determine the efficacy of a portable biofeedback device on improving sleep latency and other sleep variables such as nocturnal awake time and daytime functioning in persons with primary insomnia.
详细描述
There is evidence that when compared to normal controls, persons with insomnia exhibit increased cognitive and physiological arousal and higher overall metabolic rate during sleep, particularly at sleep onset. There is evidence that reducing this arousal may impact sleep latency and nocturnal awake time. Although relaxation treatments have been integrated into behavioral therapies, there are numerous barriers to their implementation in real world settings. The present study is designed to examine the effect of a portable biofeedback device designed to induce physiological relaxation as compared to an inactive sham control device condition in reducing sleep onset latency in persons with primary insomnia over a 4 week period at three separate research sites.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Between the ages of 18-55
- •Met DSM-IV-TR criteria for Primary Insomnia as measured by the:
- •Structured Interview for Sleep Disorders.
- •Insomnia Severity Index (>14).
- •Demonstrate Sleep Onset Latency of >=45 minutes on >= 3 nights per week greater than or equal to 6 days over the 2 week period.
- •A mean SOL >= 30 minutes over the 2 week period between Screening and Baseline visits.
- •Residential stability (1 year) and means to travel to appointments.
- •Willing to provide the name and contact information of a secondary contact person.
- •Off insomnia medications for at least one week prior to randomization and no more than 2 days of use during the first week of baseline.
- •Ability to read in English.
- •Provision of informed consent.
- •Willing to comply with daily protocol.
- •Ability to obtain a reading on the device.
排除标准
- •Been in more than 2 studies in the past 2 years
- •Terminal, progressive, and or unstable medical illness.
- •Self-reported sleep disruptive medical disorder i. Chronic Pain, Fibromyalgia, Pheochromocytoma, Hyperthyroidism, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes.
- •Current Axis I psychiatric disorder.(DSM-IV) i. Major Depressive Disorder, Depression, Generalized Anxiety Disorder, Attention Deficit Disorder, Post Traumatic Stress Disorder, Bipolar Disorder, Substance/Alcohol Use Disorders, Attention Deficit Hyperactivity Disorder, Schizophrenia/Psychotic Disorders, Delirium, Dementia, and/or Amnesic disorders, Panic Disorder w/ nocturnal panic attacks.
- •Chronic alcohol use not diagnosed in criterion
- •i. Subjects unwilling to limit their alcohol intake to 2 standard drinks per day will be excluded.
- •Raynaud's Disease
- •Regularly taking anti-anxiety medications, beta blockers or other heart medications that regulate heartbeat, bronchodilators, respiratory stimulants, simulating antidepressants, sedating antidepressants, thyroid supplements, anti-psychotics, and/or steroids.
- •Regularly taking antidepressants (Prozac, Zoloft, Paxil) and NOT on a fixed dosage for at least 1 month prior to entering the study.
- •Regularly taking medication (prescribed or over the counter) for sleep difficulties (>3x week). Sleep medications include any substance for sleep not limited to but including FDA approved sleep medications, analgesics, antihistamines, decongestants, melatonin, L-trypotophan, and velarian.
- •Unwilling to abstain from PRN sleep aides (prescribed or over the counter).
- •Restless Leg Syndrome as assessed by structured interview.
- •Symptoms of Sleep Apnea (BMI>32 and Epworth Sleepiness Scale >10)
- •Own a negative air ionizer or have used one in the past to treat insomnia.
- •If subject recognizes device during the ability to obtain a pulse rate wave reading on the device.
- •More than 5 cups (8oz) of caffeinated drinks per day and/or unwilling to limit caffeine in-take to a maximum of 3 cups a day and not after 5pm during the intervention.
- •Regular night-time shift work and rotating night-time shift work.
- •Idiopathic Insomnia.
结局指标
主要结局
Sleep latency at 4 week follow-up
次要结局
- wake time after sleep onset (WASO) at 4 week follow-up
- total awake time (SOL + WASO) at 4 week follow-up
- Shifting from moderate/severe insomnia to mild/no insomnia (Insomnia Severity Index)at 4 week follow-up
- Daytime functioning at 4 week follow-up
研究者
研究点 (2)
Loading locations...
相似试验
招募中
不适用
The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of LifeNCT06675344Robyn T. Domsic, MD, MPH160
尚未招募
不适用
Bimodal Stimulation Using Auditory and Vibrotactile Stimuli for the Mitigation of TinnitusTinnitusNCT06508060Neosensory200
已完成
不适用
A Pilot Study Examining the Efficacy of Biomodulator Treatment for Chronic Low Back PainChronic Low Back PainNCT02707094Brooke Army Medical Center75
已完成
不适用
Efficacy of a Mobile Application to Help in Weight Loss Before Bariatric SurgeryMorbid ObesityWeight LossNCT05598840Hospital Universitari de Bellvitge142
Unknown
不适用
Using ICT to Deliver i-BMI to Promote Smoking Cessation Among Smokers With Chronic DiseasesSmoking CessationNCT03983330The University of Hong Kong60